Optimization of the Linker Substructure
Journal of Medicinal Chemistry, 2008, Vol. 51, No. 20 6357
(19) Suhr, O. B.; Herlenius, G.; Friman, S.; Ericzon, B. G. Liver
transplantation for hereditary transthyretin amyloidosis. LiVer Trans-
plant. 2000, 6, 263–276.
(20) Olofsson, B. O.; Backman, C.; Karp, K.; Suhr, O. B. Progression of
cardiomyopathy after liver transplantation in patients with familial
amyloidotic polyneuropathy, Portuguese type. Transplantation 2002,
73, 745–751.
(21) Blake, C. C.; Geisow, M. J.; Oatley, S. J.; Rerat, B.; Rerat, C. Structure
of prealbumin: secondary, tertiary and quaternary interactions deter-
mined by Fourier refinement at 1.8 Å. J. Mol. Biol. 1978, 121, 339–
356.
and Environmental Research, and by the National Institutes of
Health, National Center for Research Resources, Biomedical
Technology Program, and the National Institute of General
Medical Sciences. Data for structure 6d was collected on the
in-house source, a Rigaku FR-D (Cu KR) and MAR345dtb
detector. The authors would also like to thank Drs. Xiaoping
Dai, Andre Schiefner, and Xiaojin Xu in the Wilson laboratory
for assistance with data collection.
(22) Hornberg, A.; Eneqvist, T.; Olofsson, A.; Lundgren, E.; Sauer-
Eriksson, A. E. A comparative analysis of 23 structures of the
amyloidogenic protein transthyretin. J. Mol. Biol. 2000, 302, 649–
669.
(23) Foss, T. R.; Kelker, M. S.; Wiseman, R. L.; Wilson, I. A.; Kelly,
J. W. Kinetic stabilization of the native state by protein engineering:
implications for inhibition of transthyretin amyloidogenesis. J. Mol.
Biol. 2005, 347, 841–854.
(24) Foss, T. R.; Wiseman, R. L.; Kelly, J. W. The pathway by which the
tetrameric protein transthyretin dissociates. Biochemistry 2005, 44,
15525–15533.
(25) Monaco, H. L.; Rizzi, M.; Coda, A. Structure of a complex of two
plasma proteins: transthyretin and retinol-binding protein. Science
1995, 268, 1039–1041.
Supporting Information Available: Efficacy scoring of the
previously evaluated aryl-X substructure optimization library,
detailed synthetic schemes, procedures, and characterization data
for all compounds, calculated phenolic pKa values, and tabulation
of compound purity as determined by C4 and C18 RP-HPLC. This
material is available free of charge via the Internet at http://
pubs.acs.org.
References
(1) Balch, W. E.; Morimoto, R. I.; Dillin, A.; Kelly, J. W. Adapting
proteostasis for disease intervention. Science 2008, 319, 916–919.
(26) Klabunde, T.; Petrassi, H. M.; Oza, V. B.; Raman, P.; Kelly, J. W.;
Sacchettini, J. C. Rational design of potent human transthyretin
amyloid disease inhibitors. Nat. Struct. Biol. 2000, 7, 312–321.
(27) Johnson, S. M.; Connelly, S.; Wilson, I. A.; Kelly, J. W. Biochemical
and structural evaluation of highly selective 2-arylbenzoxazole-based
transthyretin amyloidogenesis inhibitors. J. Med. Chem. 2008, 51, 260–
270.
(28) Johnson, S. M.; Petrassi, H. M.; Palaninathan, S. K.; Mohamedmo-
haideen, N. N.; Purkey, H.; Nichols, C.; Chiang, K. P.; Walkup, T.;
Sacchettini, J. C.; Sharpless, K. B.; Kelly, J. W. Bisaryloxime ethers
as potent inhibitors of transthyretin amyloid fibril formation. J. Med.
Chem. 2005, 48, 1576–1587.
(29) Purkey, H. E.; Palaninathan, S. K.; Kent, K. C.; Smith, C.; Safe, S. H.;
Sacchettini, J. C.; Kelly, J. W. Hydroxylated polychlorinated biphenyls
selectively bind transthyretin in blood and inhibit amyloidogenesis:
rationalizing rodent PCB toxicity. Chem. Biol. 2004, 11, 1719–1728.
(30) Oza, V. B.; Petrassi, H. M.; Purkey, H. E.; Kelly, J. W. Synthesis and
evaluation of anthranilic acid-based transthyretin amyloid fibril inhibi-
tors. Bioorg. Med. Chem. Lett. 1999, 9, 1–6.
(31) Oza, V. B.; Smith, C.; Raman, P.; Koepf, E. K.; Lashuel, H. A.;
Petrassi, H. M.; Chiang, K. P.; Powers, E. T.; Sachettini, J.; Kelly,
J. W. Synthesis, structure, and activity of diclofenac analogues as
transthyretin amyloid fibril formation inhibitors. J. Med. Chem. 2002,
45, 321–332.
(32) Petrassi, H. M.; Johnson, S. M.; Purkey, H.; Chiang, K. P.; Walkup,
T.; Jiang, X.; Powers, E. T.; Kelly, J. W. Potent and selective structure-
based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic
stabilization of the native state. J. Am. Chem. Soc. 2005, 127, 6662–
6671.
(33) Petrassi, H. M.; Klabunde, T.; Sacchettini, J. C.; Kelly, J. W. Structure-
based design of N-phenyl phenoxazine transthyretin amyloid fibril
inhibitors. J. Am. Chem. Soc. 2000, 122, 2178–2192.
(34) Razavi, H.; Palaninathan, S. K.; Powers, E. T.; Wiseman, R. L.; Purkey,
H. E.; Mohamedmohaideen, N. N.; Deechongkit, S.; Chiang, K. P.;
Dendle, M. T.; Sacchettini, J. C.; Kelly, J. W. Benzoxazoles as
transthyretin amyloid fibril inhibitors: synthesis, evaluation, and
mechanism of action. Angew. Chem., Int. Ed. 2003, 42, 2758–2761.
(35) Razavi, H.; Powers, E. T.; Purkey, H. E.; Adamski-Werner, S. L.;
Chiang, K. P.; Dendle, M. T.; Kelly, J. W. Design, synthesis, and
evaluation of oxazole transthyretin amyloidogenesis inhibitors. Bioorg.
Med. Chem. Lett. 2005, 15, 1075–1078.
(2) Zhang, Q.; Powers, E. T.; Nieva, J.; Huff, M. E.; Dendle, M. A.;
Bieschke, J.; Glabe, C. G.; Eschenmoser, A.; Wentworth, P., Jr.;
Lerner, R. A.; Kelly, J. W. Metabolite-initiated protein misfolding may
trigger Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 2004, 101,
4752–4757.
(3) Cohen, E.; Bieschke, J.; Perciavalle, R. M.; Kelly, J. W.; Dillin, A.
Opposing activities protect against age-onset proteotoxicity. Science
2006, 313, 1604–1610.
(4) Mu, T. W.; Fowler, D. M.; Kelly, J. W. Partial restoration of mutant
enzyme homeostasis in three distinct lysosomal storage disease cell
lines by altering calcium homeostasis. PLoS Biol. 2008, 6, e26.
(5) Dobson, C. M. Protein folding and misfolding. Nature 2003, 426, 884–
890.
(6) Selkoe, D. J. Folding proteins in fatal ways. Nature 2003, 426, 900–
904.
(7) Johnson, S. M.; Wiseman, R. L.; Sekijima, Y.; Green, N. S.; Adamski-
Werner, S. L.; Kelly, J. W. Native state kinetic stabilization as a
strategy to ameliorate protein misfolding diseases: a focus on the
transthyretin amyloidoses. Acc. Chem. Res. 2005, 38, 911–921.
(8) Westermark, P.; Bergstrom, J.; Solomon, A.; Murphy, C.; Sletten, K.
Transthyretin-derived senile systemic amyloidosis: clinicopathologic
and structural considerations. Amyloid 2003, 10 (Suppl. 1), 48–54.
(9) Westermark, P.; Sletten, K.; Johansson, B.; Cornwell, G. G. Fibril in
senile systemic amyloidosis is derived from normal transthyretin. Proc.
Natl. Acad. Sci. U.S.A. 1990, 87, 2843–2845.
(10) Buxbaum, J. N.; Tagoe, C. E. The genetics of the amyloidoses. Annu.
ReV. Med. 2000, 51, 543–569.
(11) Jiang, X.; Buxbaum, J. N.; Kelly, J. W. The V122I cardiomyopathy
variant of transthyretin increases the velocity of rate-limiting tetramer
dissociation, resulting in accelerated amyloidosis. Proc. Natl. Acad.
Sci. U.S.A. 2001, 98, 14943–14948.
(12) Jacobson, D. R.; Pastore, R. D.; Yaghoubian, R.; Kane, I.; Gallo, G.;
Buck, F. S.; Buxbaum, J. N. Variant-sequence transthyretin (isoleucine
122) in late-onset cardiac amyloidosis in black Americans. N. Engl.
J. Med. 1997, 336, 466–473.
(13) Plante-Bordeneuve, V.; Said, G. Transthyretin related familial amyloid
polyneuropathy. Curr. Opin. Neurol. 2000, 13, 569–573.
(14) Gambetti, P.; Russo, C. Human brain amyloidoses. Nephrol. Dial.
Transplant 1998, 13 Suppl 7, 33–40.
(36) Adamski-Werner, S. L.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly,
J. W. Diflunisal analogues stabilize the native state of transthyretin.
Potent inhibition of amyloidogenesis. J. Med. Chem. 2004, 47, 355–
374.
(37) Green, N. S.; Foss, T. R.; Kelly, J. W. Genistein, a natural product
from soy, is a potent inhibitor of transthyretin amyloidosis. Proc. Natl.
Acad. Sci. U.S.A. 2005, 102, 14545–14550.
(38) Green, N. S.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W.
Synthesis and characterization of potent bivalent amyloidosis inhibitors
that bind prior to transthyretin tetramerization. J. Am. Chem. Soc. 2003,
125, 13404–13414.
(39) Hammarstrom, P.; Wiseman, R. L.; Powers, E. T.; Kelly, J. W.
Prevention of transthyretin amyloid disease by changing protein
misfolding energetics. Science 2003, 299, 713–716.
(15) Sekijima, Y.; Hammarstrom, P.; Matsumura, M.; Shimizu, Y.; Iwata,
M.; Tokuda, T.; Ikeda, S.; Kelly, J. W. Energetic characteristics of
the new transthyretin variant A25T may explain its atypical central
nervous system pathology. Lab. InVest. 2003, 83, 409–417.
(16) Hammarstrom, P.; Sekijima, Y.; White, J. T.; Wiseman, R. L.; Lim,
A.; Costello, C. E.; Altland, K.; Garzuly, F.; Budka, H.; Kelly, J. W.
D18G transthyretin is monomeric, aggregation prone, and not detect-
able in plasma and cerebrospinal fluid: a prescription for central
nervous system amyloidosis. Biochemistry 2003, 42, 6656–6663.
(17) Holmgren, G.; Ericzon, B. G.; Groth, C. G.; Steen, L.; Suhr, O.;
Andersen, O.; Wallin, B. G.; Seymour, A.; Richardson, S.; Hawkins,
P. N. Clinical improvement and amyloid regression after liver
transplantation in hereditary transthyretin amyloidosis. Lancet 1993,
341, 1113–1116.
(40) Wiseman, R. L.; Johnson, S. M.; Kelker, M. S.; Foss, T.; Wilson,
I. A.; Kelly, J. W. Kinetic stabilization of an oligomeric protein by a
single ligand binding event. J. Am. Chem. Soc. 2005, 127, 5540–5551.
(18) Tan, S. Y.; Pepys, M. B.; Hawkins, P. N. Treatment of amyloidosis.
Am. J. Kidney Dis. 1995, 26, 267–285.